omeprazole has been researched along with Coronary Artery Disease in 20 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 8.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| " The aim of this study was to estimate the effects of gastric acid output suppression with rabeprazole on course of angina pectoris and results of the treadmill stress test in patients with CAD." | 5.11 | Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. ( Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Morawski, W; Pulkowski, G; Suppan, K; Swiatkowski, M, 2004) |
| "Aspirin has been the mainstay for secondary prevention of coronary artery disease to decrease early recurrence and severity of recurrent cardiovascular events." | 4.95 | Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease. ( Haseeb, S; Kagolanu, D; Lam, P; Munnangi, S; Sayedy, N; Shah, S; Stephenson, K; Viswanathan, P, 2017) |
| "Aspirin is indicated for primary and secondary prevention of cardiovascular diseases (CVD) by major guidelines." | 4.95 | Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. ( Bliden, K; Chaudhary, R; Gurbel, PA; Sharma, T; Tantry, U, 2017) |
| " If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
| "Omeprazole, a PPI, has been reported to weaken the antiplatelet effects of clopidogrel." | 1.38 | Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. ( Horiuchi, H; Ikeda, T; Imai, M; Jinnai, T; Kato, Y; Kimura, T; Makiyama, T; Shirakawa, R; Tada, T; Tazaki, J; Yamane, K, 2012) |
| "Gastro-esophageal reflux disease (GERD) may cause chest pain." | 1.33 | Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD? ( Bachórzewska-Gajewska, H; Baniukiewicz, A; Dabrowski, A; Dobrzycki, S; Kamiński, KA; Korecki, J; Musial, WJ; Prokopczuk, P, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 16 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kagolanu, D | 1 |
| Sayedy, N | 1 |
| Haseeb, S | 1 |
| Shah, S | 1 |
| Lam, P | 1 |
| Munnangi, S | 1 |
| Viswanathan, P | 1 |
| Stephenson, K | 1 |
| Simon, N | 1 |
| Finzi, J | 1 |
| Cayla, G | 1 |
| Montalescot, G | 1 |
| Collet, JP | 1 |
| Hulot, JS | 1 |
| Kruszelnicka, O | 1 |
| Świerszcz, J | 1 |
| Bednarek, J | 1 |
| Chyrchel, B | 1 |
| Surdacki, A | 1 |
| Nessler, J | 1 |
| Furtado, RHM | 1 |
| Giugliano, RP | 1 |
| Strunz, CMC | 1 |
| Filho, CC | 1 |
| Ramires, JAF | 1 |
| Filho, RK | 1 |
| Neto, PAL | 1 |
| Pereira, AC | 1 |
| Rocha, TR | 1 |
| Freire, BT | 1 |
| D'Amico, EA | 1 |
| Nicolau, JC | 1 |
| Sharma, T | 1 |
| Bliden, K | 1 |
| Chaudhary, R | 1 |
| Tantry, U | 1 |
| Gurbel, PA | 1 |
| Serebruany, V | 1 |
| Goto, S | 1 |
| Sibbing, D | 1 |
| Morath, T | 1 |
| Stegherr, J | 1 |
| Braun, S | 1 |
| Vogt, W | 1 |
| Hadamitzky, M | 1 |
| Schömig, A | 1 |
| Kastrati, A | 1 |
| von Beckerath, N | 1 |
| Neubauer, H | 1 |
| Engelhardt, A | 1 |
| Krüger, JC | 1 |
| Lask, S | 1 |
| Börgel, J | 1 |
| Mügge, A | 1 |
| Endres, HG | 1 |
| Siriswangvat, S | 1 |
| Sansanayudh, N | 1 |
| Nathisuwan, S | 1 |
| Panomvana, D | 1 |
| Fan, H | 1 |
| Zheng, Z | 1 |
| Feng, W | 1 |
| Wang, W | 1 |
| Song, Y | 1 |
| Lin, Y | 1 |
| Hu, S | 1 |
| Bhatt, DL | 1 |
| Cryer, BL | 1 |
| Contant, CF | 1 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Scirica, BM | 1 |
| Murphy, SA | 1 |
| Cannon, CP | 1 |
| Venerito, M | 1 |
| Kandulski, A | 1 |
| Malfertheiner, P | 1 |
| Southworth, MR | 1 |
| Temple, R | 1 |
| Hudzik, B | 1 |
| Szkodzinski, J | 1 |
| Danikiewicz, A | 1 |
| Wilczek, K | 1 |
| Romanowski, W | 1 |
| Lekston, A | 1 |
| Polonski, L | 1 |
| Zubelewicz-Szkodzinska, B | 1 |
| Juurlink, DN | 1 |
| Sadek, A | 1 |
| Ford, AC | 1 |
| Budzyński, J | 2 |
| Pulkowski, G | 2 |
| Suppan, K | 2 |
| Fabisiak, J | 2 |
| Majer, M | 2 |
| Kłopocka, M | 2 |
| Galus-Pulkowska, B | 1 |
| Wasielewski, M | 1 |
| Yamane, K | 1 |
| Kato, Y | 1 |
| Tazaki, J | 1 |
| Tada, T | 1 |
| Makiyama, T | 1 |
| Imai, M | 1 |
| Jinnai, T | 1 |
| Ikeda, T | 1 |
| Shirakawa, R | 1 |
| Kimura, T | 1 |
| Horiuchi, H | 1 |
| Swiatkowski, M | 1 |
| Morawski, W | 1 |
| Dobrzycki, S | 1 |
| Baniukiewicz, A | 1 |
| Korecki, J | 1 |
| Bachórzewska-Gajewska, H | 1 |
| Prokopczuk, P | 1 |
| Musial, WJ | 1 |
| Kamiński, KA | 1 |
| Dabrowski, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study[NCT01896557] | Phase 4 | 92 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in P2Y12 Reactivity Units. (NCT01896557)
Timeframe: One week after randomized treatment exposure (omeprazole or ranitidine)
| Intervention | P2Y12 Reactivity Units (Mean) |
|---|---|
| Omeprazole | 173.54 |
| Ranitidine | 153.61 |
One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in percent Inhibition of Platelet Aggregation (IPA) from baseline. IPA was calculated as the percent change in aggregability from baseline, with the formula IPA = (on-treatment aggregability minus baseline aggregability)/baseline aggregability. Since baseline aggregation is always, per definition, equal or more than on-treatment aggregation, there is no possibility that this number might be negative. (NCT01896557)
Timeframe: One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline
| Intervention | Percentage (Mean) |
|---|---|
| Omeprazole | 17.4 |
| Ranitidine | 30.1 |
After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: bioimpedance aggregometry with ADP 10 mcM as reagent (NCT01896557)
Timeframe: 1 week after drug exposure
| Intervention | Ohms (Mean) |
|---|---|
| Omeprazole | 2 |
| Ranitidine | 2.77 |
After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: PFA-100(Collagen/ADP cartridge). (NCT01896557)
Timeframe: 1 week after drug exposure
| Intervention | seconds (Mean) |
|---|---|
| Omeprazole | 95.1 |
| Ranitidine | 97.2 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
3 reviews available for omeprazole and Coronary Artery Disease
| Article | Year |
|---|---|
Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease.
Topics: Administration, Oral; Aspirin; Coronary Artery Disease; Double-Blind Method; Drug Combinations; Gast | 2017 |
Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Gastrointestinal Diseases; Gastrointestin | 2017 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
8 trials available for omeprazole and Coronary Artery Disease
| Article | Year |
|---|---|
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Clopidogrel; Coronary Artery Disease; Cytoc | 2015 |
Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; | 2016 |
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2010 |
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Artery Dis | 2010 |
Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey.
Topics: Adult; Aged; Angina Pectoris; Anti-Ulcer Agents; Coronary Angiography; Coronary Artery Disease; Cros | 2011 |
Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina Pectoris; Anti-Ulcer Agents; Benzimidazoles; Comorbi | 2004 |
9 other studies available for omeprazole and Coronary Artery Disease
| Article | Year |
|---|---|
Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Arginine; Coronary Artery Disease; Cross-Sectional St | 2016 |
Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspi | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary | 2009 |
Risk factors and prevention of upper gastrointestinal hemorrhage after a coronary artery bypass grafting operation.
Topics: Adult; Aged; Aged, 80 and over; Confidence Intervals; Coronary Artery Bypass; Coronary Artery Diseas | 2010 |
Interaction of clopidogrel and omeprazole.
Topics: Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Comb | 2010 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cardiovascular Diseases; Chemistry, Pharmaceutical; Clopido | 2011 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointest | 2011 |
Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Asian People; Aspirin; Case-Control Studies; Clopidog | 2012 |
Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD?
Topics: Adult; Aged; Anti-Ulcer Agents; Circadian Rhythm; Coronary Artery Disease; Electrocardiography, Ambu | 2005 |